WO2001003678A2 - Transdermales therapeutisches system zur anwendung von tolterodin - Google Patents
Transdermales therapeutisches system zur anwendung von tolterodin Download PDFInfo
- Publication number
- WO2001003678A2 WO2001003678A2 PCT/EP2000/006605 EP0006605W WO0103678A2 WO 2001003678 A2 WO2001003678 A2 WO 2001003678A2 EP 0006605 W EP0006605 W EP 0006605W WO 0103678 A2 WO0103678 A2 WO 0103678A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- transdermal therapeutic
- polyethylene
- mixture
- therapeutic system
- tolterodine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
Definitions
- the invention relates to a drug-containing transdermal therapeutic system for the use of tolterodine, 5-hydroxymethyltolterodine and / or their pharmaceutically acceptable salts.
- Tolterodine [(R) -N, N-diisopropyl-3- (2-hydroxy-5-methylphenyl) -3-phenylpropylamine] is a new, very effective and competitive muscarinic receptor antagonist (parasympatholytic agent). It has great affinity and specificity for the muscarinic receptor. Tolterodine is used to treat bladder incontinence and other conditions caused by an unstable bladder. When tolterodine is administered orally, the active ingredient is rapidly absorbed in the gastrointestinal tract and subsequently undergoes extensive first-pass metabolism in the liver. The metabolism takes place in two ways: the oxidation of the 5-methyl group and the dealkylation on nitrogen. The absolute Bioavailability is 30-40% and the usual and recommended oral dose is 1-2 mg twice a day because the side effects caused by the metabolites such as dry mouth, visual disturbances, gastrointestinal difficulties etc. remain tolerable for the patient.
- parasympatholytic agent parasympatholytic agent
- transdermal therapeutic systems The great advantage of transdermal therapeutic systems is that the active ingredient has a direct systemic effect after permeation through the skin.
- the required therapeutically effective dose can thus be significantly reduced and a constant blood plasma level of the active substance can be guaranteed.
- the bioavailability can be increased considerably, the liver can be relieved and the side effects caused by the metabolites such as dry mouth, gastrointestinal difficulties and visual disturbances can be reduced to a minimum.
- the simple and convenient use of plasters which remain fully effective for several days is also a major advantage for the patient. Since the system is applied externally, it can fulfill its intended function for a very long time without changing. This is absolutely impossible with oral systems, since they leave the organism after a day at the most due to the digestive activity.
- transdermal therapeutic system containing tolterodine, 5-hydroxymethyltolterodine, their pharmaceutically acceptable salts or a mixture of these.
- compositions of tolterodine or 5-hydroxymethyltolterodine are understood to mean acid addition salts. This is obtained by the reaction of the active ingredient in the free base form with pharmaceutically acceptable acids.
- Pharmaceutically acceptable acids are inorganic acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid) or organic acids (e.g.
- solvates with the active ingredient.
- Such solvates are, for example, hydrates, alcoholates and the like.
- the preferred pharmaceutically acceptable salts can e.g. Tolterodine tartrate, especially tolterodine [(R, R) tartrate] and tolterodine hydrochloride
- the transdermal therapeutic system of this invention can be a patch.
- This plaster can be a matrix or membrane system which has an impermeable cover layer and a removable protective layer.
- nylon come as an impermeable cover layer (Polyamide), nylon (polyamide) copolymer, polybutylene, polycarbonate, polyester, polyethylene terephthalate, thermoplastic polyester copolymer, polyethylene copolymer (high density), polyethylene (high-molecular-weight, high-density), polyethylene (intermediate-molecular-weight, high-density), polyethylene (linear low density), polyethylene (low density), polyethylene (medium density), polyethylene oxide, polyimide, polypropylene, polypropylene (coated
- Polyester polyethylene, polypropylene, polysiloxane, polyacrylate, ethylene vinyl acetate, polyurethane, polyisobutene or paper, mostly coated with silicone and / or polyethylene, or a mixture of these, are suitable for the removable protective layer.
- the amount of tolterodine, 5-hydroxymethyltolterodine, their pharmaceutically acceptable salts or a mixture thereof used in the transdermal therapeutic system according to the invention ranges from 0.5 to 80 mg.
- the matrix patch consists of an impermeable cover layer, one or more self-adhesive matrix layer (s) containing the active ingredient and / or permeation promoter or one or more matrix layer (s) coated with a pressure sensitive adhesive and a removable protective layer.
- the active ingredient contained in the matrix is tolterodine, 5-hydroxymethyltolterodine, their pharmaceutically acceptable salts or a mixture of these.
- Medically customary matrix formers such as polyacrylate, silicone,
- Polyisobutylene rubber, rubber-like synthetic homo-, co- or block polymers, butyl rubber, styrene / isoprene copolymer, polyurethanes, copolymers of ethylene,
- Polysiloxanes, styrene / butadiene copolymer or a mixture of these, as provided in the prior art, are used.
- Alkyl alcohol esters amine-resistant silicone in ethyl acetate or n-heptane, polyisobutylene / mineral oil or a mixture of these can be used.
- a further embodiment according to the invention is a membrane system. This consists of an impermeable cover layer, an active substance-containing reservoir or a reservoir layer, a semipermeable membrane, an optional pressure-sensitive adhesive layer and a removable protective layer.
- the reservoir contains tolterodine,
- 5-hydroxymethyltolterodine its pharmaceutically acceptable salts or a mixture of these and / or permeation promoters, stabilizers, emulsifiers, thickeners and / or customary membrane system or reservoir plaster aids.
- the reservoir or the reservoir layer lies between the cover layer and the membrane. If necessary, methyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose,
- Carboxyvinylpolymer sodium plyoxylate, carboxymethyl cellulose or a mixture of these can be used.
- the membrane which usually consists of inert polymers, in particular based on polypropylene, polyvinyl acetate, polyamide, ethylene-vinyl acetate copolymers and / or silicone, can have an effect on the release of the active ingredient.
- a pressure-sensitive adhesive for example based on polyurethane, polyisobutylene, polyvinyl ether, silicone, polyacrylate or a mixture of these, can be selected for the pressure-sensitive adhesive layer.
- the silicone-based adhesive can be silicone adhesive that is based on two main components: a polymer or adhesive, in particular polysiloxane, and a tack-increasing resin.
- the polysiloxane adhesive is usually with a crosslinker for the Adhesive, typically with a high molecular weight polydiorganosiloxane, and prepared with the resin to give a three-dimensional silicate structure using an appropriate organic solvent.
- the admixture of the resin to the polymer is the most important factor in changing the physical properties of the polysiloxane adhesives; see.
- Another example of a pressure sensitive silicone based adhesive is trimethylated silicon dioxide which has been treated with trimethylsiloxy terminated polydimethylsiloxane.
- the acrylate-based adhesives can be any homopolymer, copolymer or terpolymer consisting of various acrylic acid derivatives.
- the polyacrylate-based adhesives can be any homopolymer, copolymer or terpolymer consisting of various acrylic acid derivatives.
- the polyacrylates can be polymers of one or more monomers of acrylic acids and other copolymerizable monomers.
- the acrylate polymers can comprise copolymers of alkyl acrylates and / or methacrylates and / or copolymerizable secondary monomers or monomers with functional groups.
- the acrylate polymer consists of at least 50% by weight of an acrylate, methacrylate, alkyl acrylate or alkyl methacrylate monomer, 0 to 20% of a functional monomer, copolymerizable with acrylate, and 0 to 50% of another monomer.
- acrylate monomers such as e.g. Acrylic acid, methacrylic acid, butyl acrylate, butyl methacrylate, hexyl acrylate, hexyl methacrylate, isooctyl acrylate,
- Tridecyl methacrylate listed, which can be polymerized alone or in a mixture.
- acrylates such as, for example, acrylic acid, methacrylic acid, maleic acid, maleic anhydride, hydroxyethyl acrylate, hydroxypropyl acrylate, acrylamide, dimethylacrylamide, acrylonitrile, dimethylaminoethyl acrylate, dimethylaminoethyl methacrylate, tert.-
- Butylaminoethyl acrylate, ter.-butylaminoethyl methacrylate, methoxyethyl acrylate, vinyl acetate and methoxyethyl methacrylate can be used for the copolymerization.
- pressure-sensitive acrylates which are suitable for the invention are, ed nd in Sata's Handbook of Pressure Sensitive Adhesive Technology "Acrylic Adhesives" 2., Pp. 396-456 (D. Sata, ed.), Van Nostrand Reinhold, New York (1989).
- Mono- and / or polyhydric aliphatic, cycloaliphatic and / or aromatic-aliphatic alcohols each with up to eight C atoms, e.g. Ethanol, 1, 2-propanediol, dexpanthenol and / or polyethylene glycol; Alcohol / water mixtures; saturated and / or unsaturated fatty alcohols, each with 8-18 C atoms; terpenes; e.g. Cineol, Carveol, Menthon, Trepineol, Verbenon, Menthol, Limonen, Thymol, Cymen,
- C atoms e.g. Ethanol, 1, 2-propanediol, dexpanthenol and / or polyethylene glycol
- Alcohol / water mixtures saturated and / or unsaturated fatty alcohols, each with 8-18 C atoms
- terpenes e.g. Cineol, Carveol, Menthon, Trepineo
- Terpinen-4-ol, neomenthol, geraniol, fenchone Mixtures of terpenes and ethanol and / or propylene glycol; tea tree oil; saturated and / or unsaturated cyclic ketones; Alkyl methyl sulfoxides; saturated and / or unsaturated fatty acids, each with 8-18 C atoms; their esters and salts; natural vitamin E; synthetic vitamin E and / or vitamin E derivatives; Sorbitan fatty acid esters and ethoxylated sorbitan fatty acid esters; Azone (laurocapram); Azone mixed with alcohol; Urea; 1-alkylpyrrolidone; Block copolymers of polyethylene glycol and dimethylsiloxane with a cationic group at one end; Folate polyethylene glycol liposome, proliposome; Polyoxyethylene 10 stearyl ether; Mixture of polyoxyethylene 10 stearyl ether and glyceryl dilaurate;
- 1st step 50 g of tolterodine are abs in 950 g of a mixture of ethanol. 65% (V / G), glycerin 20% (V / G), Copherol F1300 10% (V / G) and hydroxypropyl cellulose 1% (V / G) dissolved with stirring.
- Step 2 an acrylate adhesive (ERA 1, Adhesives Research) is dissolved in sufficient ethyl acetate, depending on its dry weight, to produce an approx. 60% solution.
- the coating solution is spread on a siliconized PET film and at
- a microporous membrane eg CoTran 9711, 3 M Medica is then laminated onto the matrix.
- step 3 The solution is supplied via a peristaltic pump.
- the laminate from step 2 is welded to a filler opening with a heat-sealable protective film.
- step 1 Filling with 400 ⁇ 5% mg of solution (step 1), the reservoir is sealed by sealing and the TTS is punched out. Amount of substances per TTS:
- Copherol F1300 76 mg
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00951373A EP1194134A1 (de) | 1999-07-13 | 2000-07-12 | Transdermales therapeutisches system zur anwendung von tolterodin |
AU64340/00A AU6434000A (en) | 1999-07-13 | 2000-07-12 | Transdermal therapeutic system for the utilization of tolterodine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1999132651 DE19932651A1 (de) | 1999-07-13 | 1999-07-13 | Transdermales therapeutisches System zur Anwendung von Tolterodin |
DE19932651.7 | 1999-07-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001003678A2 true WO2001003678A2 (de) | 2001-01-18 |
WO2001003678A3 WO2001003678A3 (de) | 2001-05-25 |
Family
ID=7914576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/006605 WO2001003678A2 (de) | 1999-07-13 | 2000-07-12 | Transdermales therapeutisches system zur anwendung von tolterodin |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1194134A1 (de) |
AU (1) | AU6434000A (de) |
DE (1) | DE19932651A1 (de) |
WO (1) | WO2001003678A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108721679A (zh) * | 2016-02-03 | 2018-11-02 | 丁永新 | 一种抗炎抑菌医用敷料 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10114382A1 (de) * | 2001-03-23 | 2002-09-26 | Beiersdorf Ag | Feuchtigkeitsaufnehmende Matrix auf Silikonbasis insbesondere zur Wundversorgung und/oder pharmazeutisch/kosmetischen Hautbehandlung |
EP1424079A1 (de) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors |
MX2011011937A (es) | 2009-05-11 | 2012-01-27 | Ratiopharm Gmbh | Desfesoterodina en la forma de una sal del acido tartarico. |
JP5642790B2 (ja) * | 2010-08-03 | 2014-12-17 | 久光製薬株式会社 | 貼付剤及びその粘着力増強方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998003067A1 (en) * | 1996-07-19 | 1998-01-29 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
WO2000012069A1 (en) * | 1998-08-27 | 2000-03-09 | Pharmacia & Upjohn Ab | Therapeutic formulation for administering tolterodine with controlled release |
WO2000012070A1 (en) * | 1998-08-27 | 2000-03-09 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder |
WO2000069421A2 (de) * | 1999-05-18 | 2000-11-23 | Schwarz Pharma Ag | Transdermales therapeutisches system (tts) tolterodin enthaltend |
-
1999
- 1999-07-13 DE DE1999132651 patent/DE19932651A1/de not_active Withdrawn
-
2000
- 2000-07-12 AU AU64340/00A patent/AU6434000A/en not_active Abandoned
- 2000-07-12 EP EP00951373A patent/EP1194134A1/de not_active Withdrawn
- 2000-07-12 WO PCT/EP2000/006605 patent/WO2001003678A2/de not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998003067A1 (en) * | 1996-07-19 | 1998-01-29 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
WO2000012069A1 (en) * | 1998-08-27 | 2000-03-09 | Pharmacia & Upjohn Ab | Therapeutic formulation for administering tolterodine with controlled release |
WO2000012070A1 (en) * | 1998-08-27 | 2000-03-09 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder |
WO2000069421A2 (de) * | 1999-05-18 | 2000-11-23 | Schwarz Pharma Ag | Transdermales therapeutisches system (tts) tolterodin enthaltend |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108721679A (zh) * | 2016-02-03 | 2018-11-02 | 丁永新 | 一种抗炎抑菌医用敷料 |
CN108721679B (zh) * | 2016-02-03 | 2020-11-20 | 唐山市博世德医疗器械有限公司 | 一种抗炎抑菌医用敷料 |
Also Published As
Publication number | Publication date |
---|---|
DE19932651A1 (de) | 2001-01-18 |
WO2001003678A3 (de) | 2001-05-25 |
AU6434000A (en) | 2001-01-30 |
EP1194134A1 (de) | 2002-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200054619A1 (en) | Transdermal administration of fentanyl and analogs thereof | |
EP1301179B1 (de) | Transdermales therapeutisches system mit hochdispersem siliziumdioxid | |
US20200000739A1 (en) | Composition for the Transdermal Delivery of Fentanyl | |
US7247315B2 (en) | Compositions and medical device for transdermal delivery of a drug and methods of making and using same | |
DE10137082A1 (de) | Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol | |
EP2944324A1 (de) | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen | |
DE60311449T2 (de) | Transdermales therapeutisches system mit zwei übereinanderliegenden matrixschichten, die verschiedene affinitäten zum enthaltenen wirkstoff ausweisen | |
WO2003011291A1 (de) | Transdermales therapeutisches system (reservoir-tts) zur anwendung von pramipexol und ropinirol | |
AU2002329763A1 (en) | Composition and transdermal drug delivery device | |
WO2001001967A1 (de) | Mikroreservoirsystem auf basis von polysiloxanen und ambiphilen lösemitteln | |
JP2003313122A (ja) | ビソプロロール含有貼付剤 | |
WO2001039752A2 (de) | Transdermales therapeutisches system enthaltend leicht flüchtige wirkstoffe | |
WO1996035427A1 (de) | Transdermales therapeutisches system (tts) zur verabreichung von testosteron | |
EP1085858B1 (de) | Transdermales therapeutisches system zur anwendung von candesartan | |
WO2001003678A2 (de) | Transdermales therapeutisches system zur anwendung von tolterodin | |
JPH11209271A (ja) | 経皮吸収製剤 | |
WO2012057220A1 (ja) | 経皮吸収型製剤 | |
JPH11209270A (ja) | 経皮吸収製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000951373 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10030786 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 64340/00 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2000951373 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000951373 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |